Bristol Myers’ BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy ...

Cipla faces revenue and margin pressure due to the upcoming Revlimid patent expiry, leading to underperformance and analyst ...

Incyte INCY announced that the FDA has approved its humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, ...

The prescribed dosage for Revlimid (lenalidomide) may vary depending on a person’s individual treatment plan. Other factors, including your specific diagnosis and medical history, may affect ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month's supply. By the time David Mitchell started taking ...

Fourth-quarter Revlimid sales of $2.26 billion topped Wall Street estimates of $1.89 billion, according to Refinitiv data. Sign up here. The company expects Revlimid sales to fall to $6.5 billion ...

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID ...

His investigation into the discovery and marketing of the drug Revlimid revealed strategies employed by pharmaceutical companies to ward off competition, and keep prices of their medications high.

ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple ...

Maintenance treatment with Darzalex (daratumumab) and Revlimid (lenalidomide) resulted in superior outcomes compared with standard-of-care Revlimid alone following autologous stem cell transplantation ...